Sugi Predict

Sugi Predict / Compounds / SCHEMBL2525185

SCHEMBL2525185

SCHEMBL2525185

O=C1C=Cc2cc(Br)ccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPRC P08575 7/20 0.52
▸ CES1 P23141 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ BCHE P06276 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ IDO1 P14902 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ PTPN1 P18031 1/20 0.52
▸ ACHE P22303 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ PTPN22 Q9Y2R2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1500055 0.87 S100A4 (0.48) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL4648894 0.83 PTPRC (0.66) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL30412580 0.83 PTPRC (0.66) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL31036879 0.80 PTPRC (0.43) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL30098793 0.76 S100A4 (0.38) PTPRCS100A4BCL2CA2CA9
SCHEMBL16900338 0.75 PTPRC (0.53) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL2525379 0.75 PTPRC (0.52) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL8152499 0.75 PTPRC (0.52) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL16358234 0.75 CES1 (0.52) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL2527823 0.75 PTPRC (0.52) PTPRCCES1KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4011367-A1 COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 Dompe' Farmaceutici S.P.A. (IT) 2022-06-15 — — EP claimed
US-20230414628-A1 METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4 RAMESH SANATH KUMAR (US) 2023-12-28 — — US disclosed
EP-4011367-A1 COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 Dompe' Farmaceutici S.P.A. (IT) 2022-06-15 — — EP disclosed
CN-110464715-B Application of small molecular compound in preparation of anti-Zika virus drugs 华中农业大学 2021-09-21 — — CN disclosed
CN-111303157-A Naphthopyrazine derivative, preparation method thereof and electronic device 苏州久显新材料有限公司 2020-06-19 — — CN disclosed
CN-106558654-B Benzophenazine derivative and application thereof in organic electroluminescent device 北京鼎材科技有限公司 2020-01-14 — — CN disclosed
US-20160369237-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECH INC (US) 2016-12-22 — — US disclosed
US-8039503-B2 Lapachone compounds and methods of use thereof ARQULE, INC. (US) 2011-10-18 — — US disclosed
US-8039503-B2 Lapachone compounds and methods of use thereof ARQULE, INC. (US) 2011-10-18 — — US disclosed
US-8039503-B2 Lapachone compounds and methods of use thereof ARQULE, INC. (US) 2011-10-18 — — US disclosed
EP-1233937-B1 INHIBITION OF POLYMERIZATION OF UNSATURATED MONOMERS CROMPTON CORP (US) 2005-10-26 — — EP disclosed
US-6653414-B2 Adding to said monomer an effective amount of a mixture comprising at least one stable hindered nitroxyl compound and one quinone or hydroquinone inbibitor UNIROYAL CHEMICAL COMPANY, INC. 2003-11-25 — — US disclosed
US-20020037958-A1 Inhibition of polymerization of unsaturated monomers ADDIVANT USA, LLC 2002-03-28 — — US disclosed
EP-0439585-B1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS MAG GEORG MAYRHOFER & CO OHG (AT) 1997-10-29 — — EP disclosed
US-5314914-A Methods and compositions for combatting herpes viruses BIOMEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1994-05-24 — — US disclosed
WO-1994003432-A1 POLYHYDROXYLATED NAPHTHYL 2-CARBOXYLATE, AND QUINOLYL AND ISOQUINOLYL 3-CARBOXYLATE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-02-17 — — WO disclosed
US-5242946-A Treating herpes Viral infections BIO-MEGA, INC. (CA) 1993-09-07 — — US disclosed
US-5196478-A Polystyrene, assays EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1993-03-23 — — US disclosed
EP-0439585-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. EPIPHARM ALLERGIE SERVICE (AT) 1991-08-07 — — EP disclosed
WO-1991002768-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1991-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230414628-A1 METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4 GPX4, GPX1, MPO PTPRC 829/4885CES1 191/4885KDM4E 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.